Global media interest in HRI’s breakthrough anti-clotting drug for COVID-19

The revolutionary new anti-clotting medicine developed by Heart Research Institute researchers may hold the key to controlling the deadly blood clots caused by COVID-19.

This groundbreaking research has attracted national and international media interest due to its far-reaching impact.

Following successful phase 1 trials that demonstrated the drug’s safety in otherwise healthy patients, HRI researchers led by Professor Shaun Jackson want to urgently move into global phase 2 trials, testing the effectiveness and safety of the drug in critically ill COVID-19 patients. It could then be a matter of months before doctors around the world can use the novel anti-clotting drug to protect patients with COVID-19, potentially saving thousands of lives.

“We need to act now, and we are urgently seeking funding to get trials underway,” Professor Jackson said.

If Professor Jackson’s clinical trials are successful, his team’s innovative anti-clotting medicine could put Sydney-based medical research on the map and become a global blockbuster therapy for patients suffering COVID-19, stroke or heart disease.